JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takemori, A. E.
Right arrow Articles by Portoghese, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takemori, A. E.
Right arrow Articles by Portoghese, P. S.

Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats

AE Takemori, MM Schwartz and PS Portoghese

Department of Pharmacology, Medical School, University of Minnesota, Minneapolis.

The effects of nor-binaltorphimine (nor-BNI) and beta-funaltrexamine (beta-FNA) were studied on the diuretic activities in rats of several kappa opioid agonists including ethylketazocine, tifluadom, bremazocine and U50,488H. Nor-BNI suppressed the diuretic activity of all kappa agonists, whereas beta-FNA failed to alter the diuresis. On the other hand, beta-FNA treatment completely blocked the morphine-induced antidiuresis, whereas nor-BNI had no effect. The present data add further evidence that nor-BNI is a highly selective antagonist of kappa opioid agonists.

Volume 247, Issue 3, pp. 971-974, 12/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
H. B. Gottlieb and D. R. Kapusta
Endogenous central {kappa}-opioid systems augment renal sympathetic nerve activity to maximally retain urinary sodium during hypotonic saline volume expansion
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2005; 289(5): R1289 - R1296.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. B. Bausch, T. M. Esteb, G. W. Terman, and C. Chavkin
Administered and Endogenously Released Kappa Opioids Decrease Pilocarpine-Induced Seizures and Seizure-Induced Histopathology
J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1147 - 1155.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Zhu, L.-Y. Luo, J.-G. Li, C. Chen, and L.-Y. Liu-Chen
Activation of the Cloned Human Kappa Opioid Receptor by Agonists Enhances [35S]GTPgamma S Binding to Membranes: Determination of Potencies and Efficacies of Ligands
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 676 - 684.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin
Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys
J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics.